Mahdi Habibi-Anbouhi

Prof. Mahdi Habibi-Anbouhi

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MAMeghdad Abdollahpour-Alitappeh
Meghdad Abdollahpour-Alitappeh
MLMajid Lotfinia
Majid Lotfinia
NBNader Bagheri
Nader Bagheri
KSKoushan Sineh Sepehr
Koushan Sineh Sepehr
MHMahdi Habibi-Anbouhi
Mahdi Habibi-Anbouhi
MAMohsen Abolhassani
Mohsen Abolhassani

9 March 2018 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Closed access
MAMeghdad Abdollahpour-Alitappeh
Meghdad Abdollahpour-Alitappeh
SKSeyed Masoud Hashemi Karouei
Seyed Masoud Hashemi Karouei
MLMajid Lotfinia
Majid Lotfinia
AAAMIR AMANZADEH
AMIR AMANZADEH
MHMahdi Habibi-Anbouhi
Mahdi Habibi-Anbouhi
Rituximab is a chimeric monoclonal antibody directed against B-lymphocyte specific antigen CD20, which is used for the treatment of B-cell malignancies. However, the effectiveness of rituximab is limited partly due to treatment resistance. The aim of this study was to develop rituximab-based antibody drug conjugate (ADC) to enhance rituximab activity. In this study, monomethyl auristatin E (MMAE) was covalently conjugated to dithiothreitol -reduced rituximab via a valine-citrulline peptide linker (rituximab-vcMMAE). The conjugates were then characterized by using nonreducing sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE) and cell-based enzyme-linked immunosorbent assay (ELISA). The cytotoxic activity of the ADC was evaluated against Raji (human B-cell lymphoma; CD20-positive) and MOLT-4 (T lymphoblast; acute lymphoblastic leukemia; CD20-negative) cell lines. In addition, the colony formation assay was used to identify the propagation ability of ADC-treated cells in vitro. Results from nonreducing SDS-PAGE revealed various species of rituximab-MC-Val-Cit-PABC-MMAE (rituximab-vcMMAE), as compared with unconjugated rituximab. The binding capacity of rituximab-vcMMAE to the CD20-positive cell was similar to that of the parental rituximab. Most importantly, our results revealed that rituximab-vcMMAE was highly potent against the CD20-positive cell line, but not against the CD20-negative cell. At the same time, rituximab-vcMMAE was able to inhibit colony formation in CD20-positive cells. These data indicate that rituximab-vcMMAE may be a highly effective and selective therapy for the treatment of B-cell lymphoma.

15 July 2023 in Preparative Biochemistry & Biotechnology
Verified
Journal Article
Closed access
MIMahboubeh Irani
Mahboubeh Irani
MHMahdi Habibi-Anbouhi
Mahdi Habibi-Anbouhi
MBMahdi Behdani
Mahdi Behdani
FKFatemeh Kazemi-Lomedasht
Fatemeh Kazemi-Lomedasht
Inhibition of FGFR2 signaling is promising in targeted therapy of FGFR2-related tumors. In this study, anti-FGFR2 nanobodies (Nbs) were isolated through screening of an immune camelid phage display library. Four rounds of biopanning were carried out with commercial human FGFR2 antigen and enrichment was assessed by ELISA and phage titration. The gene of Nb was sub-cloned into the expression vector, and the recombinant vector was transformed into Escherichia coli WK6 cells. The recombinant protein was purified using Ni-NTA affinity chromatography. The anti-FGFR2 Nb (C13) was characterized by SDS-PAGE, western blotting, competitive inhibition ELISA, flow cytometry, MTT, and migration assay. C13 Nb recognized FGFR2 with high specificity and no cross-reactivity was observed with other tested antigens. The affinity of C13 Nb was calculated to be 1.5 x 10(-9) M. Results of cytotoxicity showed that C13 Nb (10 & mu;g/ml) inhibited 85% of the proliferation of T-47D cells (p < 0.001). In addition, C13 inhibited the migration of 68% of T-47D toward the source of the growth factor (p < 0.01). The flow cytometry showed that C13 Nb bound to the surface of FGFR2(+) cells, T-47D cell line (96%). Results indicate the potential of anti-FGFR2 Nb for targeted therapy of FGFR2-overexpressing tumors after complementary investigations.